25 May
2023
4basebio
PLC
("4basebio", the
"Company" or the “Group”)
4basebio and
Neomatrix announce clinical material supply agreement to develop
personalised cancer therapy utilising 4basebio’s proprietary
hpDNA™.
Cambridge, UK , 25 May
2023 – 4basebio PLC (AIM: 4BB), an innovation driven
biotechnology company enabling and accelerating development of
advanced therapy medicinal products (ATMPs) through its high
performant synthetic DNA products and non-viral, cell targeting
nucleic acid delivery platform, today announces a product supply
agreement with Neomatrix, an Italian based biotech company focused
on personalised cancer immunotherapies.
Under the agreement,
4basebio will supply clinical and preclinical DNA materials into
Neomatrix’ neoantigen cancer vaccine program. The program is
expected to start patient enrolment in early 2024. Neomatrix
will gain access to 4basebio‘s proprietary DNA products including
hpDNA™ and oeDNA™. 4basebio will manufacture and provide the
personalised clinical grade DNA products, the key component in
Neomatrix’ immunotherapy cancer treatment.
Neomatrix’ vaccine
based cancer treatment utilises the patient’s immune system to
recognise newly generated antigens (neoantigens), created by and
displayed on tumour cells. Personalised cancer vaccines require a
tumour biopsy which is sequenced to identify the neoantigens
created by cancer-specific DNA mutations. A patient specific DNA
sequence coding for such neoantigens is then designed, produced and
administered. The time between initial biopsy and vaccine
administration (“needle to needle”) is critical. 4basebio’s
enzymatically produced synthetic DNA, with its rapid manufacturing
timescales, is uniquely positioned to provide high performant DNA
products in a timely fashion.
Dr
Heikki Lanckriet, CEO and CSO for
4basebio, said: “We
are delighted to be working with Neomatrix in the delivery of
neoantigen cancer vaccines. 4basebio’s DNA products offer
significant advantages both in terms of performance and the time
required to manufacture a personalised vaccine, which is
particularly relevant where needle to needle time is paramount to
clinical outcome.”
Luigi Aurisicchio, CEO of Neomatrix,
said: “We are excited
to have 4basebio as our partner for the production of our
personalised neoantigen vaccines. The performance and quality of
4basebio’s DNA products as well as the speed of manufacture have
driven our decision to partner with
4basebio.”
For further
enquiries, please contact:
4basebio
PLC
+44 (0)12 2396 7943
Heikki
Lanckriet
Nominated
Adviser
+44 (0)20 7213 0880
Cairn Financial Advisers
LLP
Jo
Tuner / Sandy
Jamieson
Broker
+44 (0)20 7220 0500
finnCap
Ltd
Geoff
Nash / Richard Chambers /
Charlotte
Sutcliffe
Lionsgate
Communications (Media
Enquiries) +44 (0)77
91892509
Jonathan
Charles
Notes to
Editors
About
4basebio
4basebio (AIM: 4BB)
is an innovation driven life biotechnology company focussed on
accelerating the development of advanced therapy medicinal products
(ATMPs) through its high performant synthetic DNA products and
non-viral, cell targeting nucleic acid delivery platform. The
Company’ objective is to become a market leader in the manufacture
and supply of high quality synthetic DNA products for research,
therapeutic and pharmacological use as well as development of
target specific non-viral vectors for the efficient delivery of
payloads in patients. The company is offering GMP compliant DNA
starting materials suitable for use in AAV viral vector production
as well as mRNA vaccine and therapeutics
production.
About
Neomatrix
Neomatrix is a
biotech company with more than 15 years of experience and proven
expertise in drug discovery in oncology and is recognised for the
design and implementation of a number of innovative technologies,
including that of DNA gene therapy. Neomatrix’ core expertise is
its experience in the prediction of neoantigens with an
electroporation delivery system, a technology that can be used for
a variety of clinically useful applications, from vaccine
development to somatic gene therapy.
Forward-looking
statements
This announcement may
contain certain statements about the future outlook for the
4basebio. Although the directors believe their expectations
are based on reasonable assumptions, any statements about future
outlook may be influenced by factors that could cause actual
outcomes and results to be materially
different.